A Phase 1, Randomized, Double-blind, Placebo-controlled Study To Assess The Safety, Tolerability, And Pharmacokinetics Of Single Escalating Oral Doses Of Pf-06865571 In Healthy Adult Subjects
Phase of Trial: Phase I
Latest Information Update: 17 Aug 2017
At a glance
- Drugs PF 06865571 (Primary)
- Indications Non-alcoholic steatohepatitis
- Focus Adverse reactions
- Sponsors Pfizer
- 10 Aug 2017 Status changed from recruiting to completed.
- 14 Jul 2017 Planned End Date changed from 24 Jun 2017 to 14 Jul 2017.
- 14 Jul 2017 Planned primary completion date changed from 24 Jun 2017 to 14 Jul 2017.